Asthma Self Management Articles & Analysis
48 news found
Bedfont® Scientific Ltd., world leaders in breath analysis with over 47 years of knowledge in designing and manufacturing medical breath analysis devices, welcomes the recent update to the National Institute for Health and Care Excellence (NICE) guidelines on asthma management. Bedfont® manufactures the NObreath® Fractional exhaled Nitric Oxide (FeNO) device, which aids in diagnosing ...
Vitalograph is proud to announce that it a FeNO by NIOX® UK channel partner. Spirometry and FeNO present physicians with complementary diagnostic data to inform asthma care pathways. NIOX VERO® is non-invasive, simple-to-use, and provides rapid standardised FeNO measurements. It is a point-of-care device for assessing airway inflammation in patients with respiratory problems. With over ...
There are many known asthma triggers, but one of the more common ones is exposure to elevated levels of mold. This information is important for asthmatics, especially those living in Puerto Rico which has some of the highest asthma rates in the United States. Across the entire country, asthma caused 5.8 million physician office visits and 1.6 million emergency department visits as recently as ...
Circassia Pharmaceuticals plc, (“Circassia” or “the Company”; LSE: CIR) announces that the Board has concluded that it is in the best interests of the Company to terminate the development and commercialisation agreement between the Company and AstraZeneca UK Limited, a subsidiary of AstraZeneca plc (LSE/STO/NYSE: AZN) (AstraZeneca) for the U.S. commercial rights to ...
Circassia Pharmaceuticals plc (“Circassia” or “the Company”; LSE: CIR), a specialty pharmaceutical company focused on respiratory disease, today announces the US launch of Duaklir® for the maintenance treatment of chronic obstructive pulmonary disease (COPD) at the American College of Chest Physicians’ CHEST Annual Meeting 2019, which is currently ongoing in New ...
Abionic SA, the developer of proprietary disruptive nanotechnology based rapid diagnostic solutions, and Genentech, a member of the Roche Group, announced today a strategic agreement to develop and provide an In Vitro Diagnostic (IVD) Asthma Test Panel using Abionic’s POC abioSCOPE® platform in the United States. Abionic’s POC abioSCOPE®, a compact, ultra-fast medical device ...
Circassia Pharmaceuticals plc (“Circassia” or “the Company”; LSE: CIR), a specialty biopharmaceutical company focused on respiratory disease, today announces the appointment of Jonathan Emms to the newly-created role of Chief Operating Officer (COO). As COO he will further strengthen Circassia’s commercial focus and lead the Company’s global commercial strategy ...
Circassia Pharmaceuticals plc (“Circassia” or “the Company”; LSE: CIR), a specialty pharmaceutical company focused on respiratory disease, today announces the full publication of the Tudorza® phase IV ASCENT study in the prestigious Journal of the American Medical Association*. The ASCENT study was conducted in patients with moderate-to-very severe chronic obstructive ...
Data showing reduction in COPD exacerbations and no increase in major cardiovascular events vs placebo added to label – – Tudorza® is the only product in its class with these data in the label Circassia Pharmaceuticals plc (“Circassia” or “the Company”; LSE: CIR), a specialty pharmaceutical company focused on respiratory disease, today announces the US ...
Oxford, UK – 11 December 2018: Circassia Pharmaceuticals plc (“Circassia” or “the Company”; LSE: CIR), a specialty pharmaceutical company focused on respiratory disease, today announces it has issued a notice of option exercise to AstraZeneca to acquire the full US commercial rights to Tudorza® (aclidinium). Circassia currently promotes the COPD treatment in the ...
Circassia Pharmaceuticals plc (“Circassia” or “the Company”; LSE: CIR), a specialty pharmaceutical company focused on respiratory disease, today announces that the United States Food and Drug Administration (FDA) has confirmed it has completed its validation for completeness, and accepted for filing and review, the previously submitted Duaklir® New Drug Application ...
Duaklir® NDA for treatment of chronic obstructive pulmonary disease (COPD) Tudorza® sNDA for inclusion of COPD exacerbation reduction and cardiovascular safety data in label Circassia Pharmaceuticals plc (“Circassia” or “the Company”; LSE: CIR), a specialty pharmaceutical company focused on respiratory disease, today announces the submission of a New Drug ...
Circassia Pharmaceuticals plc (“Circassia” or “the Company”; LSE: CIR), a specialty pharmaceutical company focused on respiratory disease, today announces the presentation of positive clinical data from the Tudorza® Pressair® phase IV ASCENT study and Duaklir® Pressair® phase III AMPLIFY study at the American Thoracic Society (ATS) 2018 International ...
In 2013, students missed 13.8 million school days due to asthma, making the disease a leading cause of school absenteeism according to the Centers for Disease Control and Prevention (CDC). As recently as 2015, the agency reports that 1 in 12 children had asthma. Asthma is a long-term, inflammatory disease that causes the airways of the lungs to tighten and constrict, leading to wheezing, ...
Managing students’ asthma and limiting their exposure to asthma triggers is a challenge in any school district. Following the devastating 2017 hurricane season, this task became all that much more difficult in schools across Puerto Rico. This was due in large part to the widespread damage that occurred in many school buildings that allowed for the growth of mold, a common asthma trigger. ...
Today, the IAQ Video Network and Cochrane & Associates announced the release of their latest educational video. Their newest production discusses the impact asthma has on students and identifying asthma triggers in schools to help manage the condition. “As recently as 2015, the CDC reports that 1 in 12 children had asthma,” said Paul Cochrane, President of Cochrane and ...
The month of May is recognized as Asthma Awareness Month across Puerto Rico and in many places around the globe. As one of the most common chronic lung diseases impacting approximately 19% of the islands’ population, the condition has a direct impact on countless families, schools, institutions and businesses. Nationwide, the Centers for Disease Control and Prevention (CDC) reports that ...
May is recognized as National Asthma and Allergy Awareness Month across the United States. Asthma is a serious respiratory condition that can be life-threatening in some circumstances. People with the condition are often exposed to numerous known asthma triggers in their homes, schools, and work environments. Occupational asthma, also referred to as work-related asthma, is the most common ...
Asthma is a major public health issue, affecting nearly 23 million people and disproportionately affecting low-income and minority communities. Although there is no cure for asthma yet, asthma can be controlled through medical treatment and management of environmental triggers. May is Asthma Awareness Month. EPA supports Asthma Awareness Month by increasing public awareness of the asthma ...
One in 10 kids in America suffers from asthma, and communities of color and low-income families are disproportionately impacted. During Asthma Awareness Month, the U.S. Environmental Protection Agency recognizes two leading asthma management programs -- Green and Healthy Homes Initiative (GHHI) in Baltimore, Md. and Le Bonheur Children’s Hospital CHAMPS Program in Memphis, Tenn. -- for ...